The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Recent and upcoming data on axi-cel for patients with NHL
Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, talks on the approval of axicabtagene ciloleucel (axi-cel) for the treatment of patients with non-Hodgkin lymphoma (NHL), highlighting data at four years of follow-up which has demonstrated around 40% control of large B-cell lymphomas. Prof. Jäger also comments on the benefits of using axi-cel in earlier lines of therapy. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
